

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Burrows et al.

Application No. 09/847,172

RECEIVED

DEC 14 2001

Filed: May 1, 2001

For: RECOMBINANT MHC MOLECULES USEFUL
FOR MANIPULATION OF ANTIGEN-
SPECIFIC T-CELLS


Examiner: To be assigned

Date: December 5, 2001

Art Unit: 1644

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on December 5, 2001 as Express Mail, Label No. EL761161399US, in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 2327, ARLINGTON, VIRGINIA, 22202.


Susan Alpert Siegel, Ph.D.
Agent for Applicant

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SECOND PRELIMINARY AMENDMENT

Prior to examination of the above-identified application, please amend the application as follows:

In the Specification:

Please replace the paragraph on page 10, lines 11-24 with the following:

Fig. 13 is the nucleotide and protein sequence of human HLA-DR2-derived RTL303 (SEQ ID NO: 43 and 44, respectively). RTL303 was derived from sequences encoding the beta-1 and alpha-1 domains of HLA-DR2 (human DRB1*1501/DRA*0101) and sequence encoding the human MBP85-99 peptide. Unique NcoI, SpeI and XhoI restriction sites are in **bold**. The end of the beta-1 domain and start of the alpha-1 domain are indicated by an arrow (▼). RTL303 contains an in-frame peptide/linker insertion encoding the human MBP85-99 peptide (**bold**), a flexible linker with an embedded thrombin cleavage site (23), and a unique SpeI restriction site which can be used for rapidly exchanging the encoded amino-terminal peptide. RTL301 is identical to RTL303 except for a single point mutation resulting in an F150L